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ABSTRACT 
It is well established that exposure to virtual motion environments (VME) 
can elicit postural instability (PI) in addition to motion sickness (MS).   While 
research has found sex differences in motion sickness, the results of 
experimental studies are equivocal regarding these differences, and previous 
studies utilizing VME have failed to address the factor of sex differences in terms 
of hormonal fluctuations, which may also be instrumental in behavioral responses 
to VME, such as PI.  The intent of this investigation was to determine whether 
exposure to VME, during various phases of the menstrual cycle (premenstrual, 
permenstrual, ovulation) would reveal sex differences in MS and PI during some 
phases, but not others.  The first experiment involved men and women 
completing Daily Living Logs for a period of 40 days to provide a baseline for any 
sex differences (and for women, menstrual phase differences) in motion related 
activity and symptomatology.  The second experiment involved 24 participants (6 
men) viewing a rotating Archimede’s spiral for a period of twenty minutes.  
Exposures were timed to place each woman in three phases of her menstrual 
cycle; men were exposed by yoking their exposure time to a female counterpart.  
Multiple measures of PI and MS were recorded before, after and during 
exposure.  Results of the first experiment found no significant effects of sex or 
phase upon symptomatology, revealing no support for the theory of a reporting 
bias as influencing sex differences in MS or PI elicited in the laboratory.  The 
second experiment found no significant effect of sex of phase upon any of the PI 
measures, but found significant interaction effects of sequence and phase, as 
 xii
well as sequence and sex, upon reported magnitude ratings of illusory self-
motion perception.  There were also significant effects of sex found upon 
measures of MS, with women reporting more discomfort to exposure to motion 
stimulation, as compared to men.  There were no significant effects of phase 
upon any of the MS measures.  While these findings show no support for a 
reporting bias influencing the sex differences found experimentally induced MS, it 
yields no evidence to support a hormonal influence on these differences. 
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CHAPTER I:  INTRODUCTION 
 
 Sex differences have always been a popular topic among scientists and 
nonscientists alike.  Research has sometimes addressed this issue in terms of 
physiological as well as psychological sex differences between men and women.  
As occupational margins between men and women have narrowed, thoughtful 
consideration of these differences has become necessary, encouraging the 
incorporation of human factors in order to maintain and improve occupational 
performance and safety.   In addition, as many workplaces become increasingly 
automated and require fewer human participants, these factors become highly 
important, particularly within dynamic motion environments.   
Challenges encountered within dynamic motion environments have the 
potential to compromise not only cognitive task performance, but physical 
performance measures as well.  These physical tasks include a variety of 
perceptual-motor skills, some of which may involve gross as well as fine motor 
skills such as manual dexterity, fine manipulation, and ocular smooth pursuit, 
saccades or fixation.  In addition, any deficits to gross motor performance may 
compromise both postural stability as well as locomotion, and possibly lead to 
accidents or injuries.  In combination with the trend of a reduced number of 
human participants employed in dynamic motion environments, it is essential to 
address any significant differences in these types of perceptual-motor tasks as 
the critical number of employees within these types of work environments 
dwindles.   
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Somatic complaints have also accompanied exposure to such dynamic 
environments.  Many who have traveled over land, at sea or in the air have 
experienced severe discomfort.  This adverse reaction to motion environments 
has been termed motion sickness (MS) (Dichgans & Brandt, 1973; Money, 1970; 
Reason & Brand, 1975).  The use of the term MS has been attributed to Irwin 
(1881) who suggested that seasickness might better be called MS because “not 
only does it occur on lakes and even on rivers, but as is well know, a sickness 
identical in kind may be induced by various other motions than that of turbulent 
water …”.  MS has been elicited by way of a diverse assortment of motion and 
simulated motion environments, characterized by a broad spectrum of ill effects, 
the susceptibility to which has been found to be more prevalent in women than in 
men (Nieuwenhuijsen, 1958; Reason & Brandt, 1975).   
 
Sex Differences 
Research has revealed a number of physiological differences between 
men and women, both within reproductive and non-reproductive body systems.  
The reproductive system of women is distinct from that of men within a multitude 
of measures.  Sexual differentiation of the external and internal genitalia has 
been found to be dependent upon activity of the endocrine system, which also 
influences the development of a sexually differentiated neurological system 
(Gorski, 2000).    
Sex hormones have been found to be highly influential in the development 
of a number of brain and reproductive structures.  As early as the stage of testes 
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differentiation during embryonic development, hormones produced by the testes 
(müllerian duct inhibiting hormone, testosterone, and dihydrotestosterone) begin 
to govern development of both male internal and external genitalia; the absence 
of the testes stimulates the development of female genitalia (Gorski, 2000; Neal, 
2002).   In addition, while the hormone estrogen has been found to be necessary 
for the masculinization of the brain, it is also highly instrumental in the 
development of the female brain (Gorski, 2000; Neal, 2002).   During the critical 
period of development, these types of hormones have been found to induce 
organizational effects on the brain (Sanders & Wenmoth, 1998).  Such structural 
distinctions in the human nervous system have included: size differences in a 
number of nuclei of the stria terminalis, anterior hypothalamus, preoptic area, and 
spinal cord (larger in men than women); size differences in the corpus collosum, 
anterior commissure, and massa intermedia (larger in women as compared to 
men); shape differences in the corpus callosum (more bulbous in women) and 
suprachiasmatic nucleus (more elongated in women); and greater asymmetry in 
the planum temporale in men (Gorski, 2000).   In addition, research has also 
shown significant sex differences in musculoskeletal development and peripheral 
motor system behavior as well (Field & Pellis, 1998).  However, whether central 
nervous system differences, such as these, influence more peripheral systems, 
or whether peripheral differences influence neural development, is still unknown. 
Research has found that not only does the endocrine system have an 
organizing effect during development; hormones such as those described above 
also have an activating effect as the individual develops into adulthood (Field & 
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Pellis, 1998; Neal, 2002).  The endocrine system in women regulates the ovarian 
cycle.  The ovarian cycle begins with the onset of menstruation and continues 
through day four of the typical female menstrual cycle.  During this stage there is 
a slight increase in follicular stimulating hormone, as well as lowered levels of 
both estrogen and progesterone (Gorski, 2000; Neal, 2002).  This stage is 
followed by the proliferative stage, which continues to around day fourteen of the 
average female cycle.  During this stage there is a surge in luteinizing hormone, 
as well a slight increase in follicular stimulating hormone, and increased levels of 
estrogen (Gorski, 2000; Neal, 2002).  This stage culminates with ovulation.  The 
secretory stage follows through around day twenty-one of the cycle.  This stage 
is dominated by increased levels of progesterone, a drop in luteinizing hormone 
and decreased levels of estrogen (Gorski, 2000; Neal, 2002).  The final stage is 
the luteolytic phase, which continues until the onset of the following cycle.  This 
stage involves a leveling of the luteinizing hormone, estrogen and progesterone, 
and a slight increase in levels of follicular stimulating hormone (Gorski, 2000; 
Neal, 2002).  In the follicular phase, estrogen has been found to be secreted at a 
rate of 60 g/day; by the ovulatory phase, estrogen often reaches a secretion rate 
of 400 to 900 g/day; and during the luteal phase, approximately 300 g/day of 
estrogen are secreted (Gill, 1985). 
Reproductive hormones may be measured in a number of different 
manners of both sampling and processing methodology (Snowden & Ziegler, 
2000).  While blood and urine samples have been the routine means of 
measuring hormone levels, these methods are costly in that blood samples 
 5
require venipuncture, a licensed professional is needed to collect and store the 
specimen, and urine samples require special handling to prevent contamination 
of the hormones.  Feces, while another means of sampling for reproductive 
hormones, is messy in more than one meaning of the word.  This type of sample 
captures hormones accumulated over an extended period of time, and thus is not 
specific to the time of collection.   Lastly, saliva sampling is another means of 
measuring reproductive hormones.  This type of measure, in addition to having 
the advantage of being non-invasive and easy to collect and handle, has been 
found to correlate well with free levels of circulating hormones.  Estradiol, a 
hormone readily sampled through saliva, has been found to be a highly 
physiologically active form of estrogen readily available for analysis of estrogen 
levels in female subjects (Becker, et al, 2004; Gill, 1985).   
While most animal studies look at dependent variables in terms of the 
above four stages of the menstrual cycle, research on human participants has 
divided the cycle into three, rather than four stages (Fridén, Hirschberg, Saartok, 
Bâckström, Leanderson & Renström, 2003; Larsen, Anniko, Nakagawa & 
Watanabe, 1998; Sanders & Wenmoth, 1998).  These stages are entitled the 
early follicular or permenstrual phase (day 2-5 of cycle), the ovulatory phase (day 
11-14 of cycle), and the mid-luteal or premenstrual phase (day 18-21 of cycle) 
(Fridén, et al, 2003; Grunfeld, et al, 1998; Grunfeld & Gresty, 1998; Neal, 2002). 
Both sex and phase of the female menstrual cycle have been implicated in 
differences found in a number of behavioral measures.   Significant sex 
differences have been found in the organization of complex motor behavior 
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patterns in many different species of mammals (Field & Pellis, 1998), including 
humans (Fridén, et al, 2003; Larsen, et al, 1998).   
Sex and phase have also been predictive of cognitive functioning, women 
performing better than men on verbal tasks, men scoring higher than women on 
mathematical and visual-spatial tasks, with significant changes occurring in these 
measures over the course of the menstrual cycle (Sanders & Wenmoth, 1998).  
Greater asymmetry has been found between the sexes in right hemisphere tasks 
(mathematical and visual-spatial) and left hemisphere tasks (verbal tasks) when 
estrogen levels are high (ovulation phase).  Similarly, reduced asymmetry has 
been found between men and women when estrogen levels are low (mid-luteal 
or permenstrual phase). Performance measures have found improved spatial 
abilities in women during menstruation, as compared to ovulation, with better 
performance when estrogen levels are low rather than high (Hampson & Kimura, 
1992).   
Other studies have found the sex of the individual to also be predictive of 
self-orientation perception, women with a tendency to be more field dependent 
than men (Darlington & Smith, 1998; Scholar & Smith, 1990; Tremblay, Elliot & 
Starkes, 2004).  However, contrary to those findings, a recent study conducted in 
our laboratory found that in terms of in self-orientation judgments, while men 
were significantly better when descending to 90° both with eyes open and closed, 
women were significantly more accurate than men with their eyes closed when 
ascending to 75° and 105° angles, and were more accurate than men at the 105° 
angle with their eyes open (May, Flanagan, Foss, Simineaux & Dobie, 2005).   
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Research has also found measures of the autonomic division of the 
peripheral nervous system, such as heart rate, to show a significant effect of 
phase of the female menstrual cycle in young women (Leicht, Hirning & Allen, 
2003; McCarthy & Becker, 2002; Mercuro, Podda, Pitzalis, Zoncu, Macia, Melis & 
Rosano, 2000; Yildirir, Kabakci, Akgul, Tokgozoglu & Oto, 2002).  In addition, 
recent studies have revealed significant effects of sex in measures of postural 
balance, with older women being more stable than older men, and younger 
women being less posturally stable than younger men (Larsen, et al, 1998).  
Another study further revealed a significant effect of menstrual phase upon 
postural stability, with women being less stable during the mid-luteal 
(premenstrual) phase, when estrogen is low (Fridén, et al, 2003).   
Research in sports medicine has also revealed significant sex differences 
in the rates of sports related injury, with women sustaining far more knee injuries 
than men (Chandy & Grana, 1985; Gray, et al. 1985; Hewett, 2000; Hewett, et 
al., 1996; Huston & Wojtys, 1996; Zelisko, Noble & Porter, 1982; Malone, et al, 
1993).  One theory proposed to explain this phenomenon implicates female 
reproductive hormones, such as estrogen, progesterone, and relaxin (Chandy & 
Grana, 1985; Huston & Wojtys, 1996; Zelisko, Noble & Porter, 1982; Haycock & 
Gillette, 1976).   
Estrogen has been found to directly influence the female neuromuscular 
systems, by increasing joint laxity and muscle fatigue, and slowing muscle 
relaxation (Booth & Tipton, 1970).  Levels of estradiol have been found to be 
positively related to muscle fatigue as well as negatively related to ligament 
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strength and speed of muscle relaxation (Florini, 1986; Sarwar, Beltran & 
Rutherford, 1996).  Estrogen also exerts its influence on neuromuscular systems 
indirectly via its effects on performance (Lebrun, 1994).  Decreased skill 
performance has been found in women during the midluteal phase (Posthuma, et 
al, 1987) and decreased injury rates during the permenstrual phase (Wojtys, et 
al, 1998; Myklebust, et al, 1998).  By stabilizing reproductive hormone levels to 
prevent the ovulatory surge, findings such as these appear to diminish when oral 
contraceptives are utilized (Moller-Nielson J, Hammar, 1989; Moller-Nielson J, 
Hammar, 1991).   
 
Motion Sickness 
Studies have approached sex and motion sickness from a number of 
perspectives, and have generally found sex to be significantly related to MS 
susceptibility.  Differences between men and women have been measured in 
terms of group differences in motion exposure, fitness, history of MS, in addition 
to episodes of MS and changes correlating with different stages within the female 
menstrual cycle.   
A survey study conducted by Lentz and Collins (1977) revealed that self-
reported susceptibilities to MS indicated less experience with various motion 
situations as compared to those who report low susceptibility to MS.  In addition, 
while they found a greater proportion of women report high susceptibility to MS 
as compared to men, this difference was not statistically significant.  However, 
recent investigation has found that while women report more sickness, this 
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difference cannot be accounted for by lack of experience, as there are no 
significant differences in physical activities prior to age 18 (Dobie, McBride, 
Dobie Jr. & May, 2001). 
In terms of diagnosed impairments, MS in women has been related to 
levels of neuroticism, as well as related to vestibular disturbances (Bick, 1983).  
Again, however, a study found that while women report MS more often than men, 
this cannot be accounted for by differences in physical activities prior to age 18, 
which could be seen as an indicator of physical health and fitness (Dobie, et al., 
2001).  A survey of over 4000 college students found that while women report 
more susceptibility to MS, men rated themselves as having more muscular 
coordination which may account for this difference (Lentz & Collins, 1977).  In 
addition, report of symptoms of migraine has been found to covary with the report 
of MS, more often in women than in men, which may also be a predictive 
indicator for MS (Grunfeld, Price, Goadsby & Gresty, 1998). 
The most robust sex difference revealed in the literature shows that 
women report a greater history of MS, as compared to men (Crush, 1976; Abe, 
Amatomi & Kajiyama, 1970; Bakwin, 1971; Deich & Hodges, 1973; Mirabile Jr. & 
Ford, 1982; Park, 1998; Sharma & Aparma, 1997; Turner & Griffin, 1999; 
Yardley, 1989).  Women report a greater history of MS in a dynamic motion 
medium (Mirabile, 1972; Mirabile, Glueck & Stroebel, 1979; Park & Hu, 1999).  
This difference has been explained from a biological perspective; a difference of 
the common emetic pathway, functioning for survival of the species exposed to a 
noxious motion environment (Golding, 1998).  However, these data could also be 
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the result of a reporting bias, women more apt to report somatic discomfort.  A 
study on Suncus Murinus found an effect of sex of the monkey upon sickness 
elicited from low frequency motion stimulation, with male subjects having a 
higher frequency, and shorter latency to onset of emesis (Matsuki, Wang, Okada, 
Tamura, Ikegaya, Lin, Hsu, Chaung, Chen & Saito, 1997).  These findings could 
be explained by the lack of social inhibition existing within these monkeys, the 
contribution of which in human subjects may prevent their reporting discomfort or 
emesis, thereby contributing to the sex differences found in human studies. 
A few other human studies, however, have also failed to find significant 
differences in history of MS between men and women (Grunfeld, et al., 1998; 
Hamid, 1991).  Some have actually found a higher incidence of reported history 
in men (Grunfeld & Gresty, 1998).  These findings are unusual though, and could 
be attributable to a number of different experimental factors.   Women tend to 
report a greater history of, and have been found more susceptible to, MS as 
compared to men, both in laboratory studies and in non-laboratory based motion 
environments, often with subjects reporting a history of MS (Flanagan, May, 
Dobie, Dunlap & Blancaneau, 2002; Aust, Hordinsky & Schmelzer,1980; Collins 
& Lentz, 1977; Gahlinger, 2000; Hearon, Fischer & Dooley, 1998; Lawther & 
Griffin, 1988; Mirabile & Glueck, 1980; Stanney, Kennedy, Drexler & Harm, 1999; 
Turner, Griffin & Holland, 2000).  However, these results have also been found in 
subjects with little to no reported history of MS (Flanagan, May & Dobie, 2005).  
While one study addressing the interaction between the sex of the subject and 
that of the experimenter failed to show a significant interaction of these factors 
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upon MS, this did not preclude the discovery of a main effect of sex of subject 
upon report of MS symptomatology (Jokerst, Fazio, Gianaros, Stern & Koch, 
1999). 
Once again, some studies have failed to find significant differences in the 
incidence in symptomatology between women and men, even in the presence of 
significantly different histories of MS (Cheung, Money & Jacobs, 1990; Clark & 
Steward, 1973; Cooper, Dunbar & Mira, 1997; Hu, Glaser, Hoffman, Stanton & 
Gruber, 1996; Owen, Leadbetter & Yardley, 1998; Sharma, 1980; Ungs, 1989; 
Woodman & Griffin, 1997).  These findings however, may be attributable to the 
influence of a self-selection process, in which sensitive women may not choose 
to participate in this sort of experiment.  For example, a survey of students over 
the course of the semester revealed that although in the beginning of semester 
there were no significant differences between levels of susceptibility or sex for 
those choosing to participate in MS research, later in the semester non-
susceptibles were significantly more likely to volunteer than susceptibles; women 
more willing to volunteer than men (Lentz & Collins, 1977).  In addition, while one 
study reported a tendency for women to be slightly more sensitive during Coriolis 
stimulation, which was not statistically different from men, the author noted that 
this might have been due to the influence of the selection process, in which 
sensitive women might not choose to volunteer for this sort of experiment 
(Woodman & Griffin, 1997). 
A recent study conducted in our laboratory replicated the findings that 
women report a greater history of MS than men, when interrogated with MS 
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history questionnaires (Flanagan, May & Dobie, 2005).  In these analyses, we 
also examined the hypothesis that those reporting that they are prone to MS are 
less likely to volunteer for MS provocative experiments than those who are MS 
resistant.  We found that MS prone individuals were actually more likely to 
volunteer for motion experiments if they felt they might benefit from such 
experience.  Using a subset of these participants, men and women were 
exposed, during two separate sessions, to visually-elicited apparent motion, with 
and without voluntary head motion (pseudo-Coriolis stimulation).  Results of this 
study revealed women reported significantly more MS during and after exposure 
to either condition, but they exhibited less tolerance with head movements, than 
with head restriction.  These results indicate that laboratory manipulations that 
are more provocative of MS and measures of tolerance to provocative stimulation 
reveal reliable sex differences.  However, this study failed to address the 
possible influence of the female menstrual cycle, which may contribute to sex 
differences elicited in measures of MS.   
Grunfeld and colleagues conducted investigations into the relationship 
between the female menstrual cycle and episodes of MS (Grunfeld, et al., 1998; 
Grunfeld & Gresty, 1998).  While they found decreased MS during ovulation, 
days 13-15 of the menstrual cycle in women participating in an around the world 
yacht race, they neglected to look at fluctuations in reporting of other somatic 
complaints which might also have varied across the course of the menstrual 
cycle, without the contribution of a dynamic motion environment.   
 13
However, studies conducted by Cheung and colleagues (Cheung & Hofer, 
2002; Cheung, Heskin, Hofer & Gagnon, 2001) failed to find significant 
differences in the incidence of symptomatology in women as a function of the 
phase of their menstrual cycle.  One of their studies found these differences to be 
related to participants’ level of anxiety upon stimulation (Cheung, Heskin, Hofer & 
Gagnon, 2001).  These findings may be compromised by underlying symptoms 
of the female menstrual cycle, the severity of which have been found to wax and 
wane over its normal monthly course (Brooks-Gunn & Ruble, 1992; Woods, 
1999).  Most women report changes in both their bodies and their moods that 
seem to vary with the course of their menstrual cycle.  These changes are often 
considered a normal part of being a woman (Woods, et al, 1987).  A substantial 
body of literature supports the existence of such menstrual cycle fluctuations 
(Palmer, Lambert & Richards, 1991; Sveinsdotter & Backstrom, 2000).  While an 
abundant amount of research has been conducted upon these types of 
symptoms within samples from clinical populations (i.e., Premenstrual Syndrome 
and Premenstrual Dysmorphic Disorder), manifestations of less severe 
fluctuations which occur in non-clinical populations that do not suffer from 
debilitating symptoms and who do not seek treatment for these cyclical changes, 
is of more interest to the area of research of motion perception as they may be 
implicated in the reporting of MS.   
These studies underscore the need to clarify the factors contributing to 
sex differences in MS.  Questions remain as to whether these findings are 
attributable to physiological factors, such as menstrual phases, to reporting 
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characteristics, such as frequency of somatic complaints, or to a combination of 
these factors. 
 
Postural Stability 
Sex differences have also been described in reference to gross motor 
skills, such as postural stability.  Studies conducted in our laboratory have 
replicated many previous research investigations, in revealing a higher incidence 
of postural instability (PI), both in men and women, during exposure to visually 
elicited apparent motion compared to static scenes (Bles & Kapteyn, 1977; 
Bronstein, 1986; Cobb & Nichols, 1998; Diener, Horak & Nashner, 1988; 
Guerraz, Sakellari, Burchill & Bronstein, 2000; Kapteyn & Bles 1977; Previc, 
1992; Reason, Wagner & Dewhurst, 1981; Reinhardt-Rutland, 1981; White, Post 
& Leibowitz, 1980).  This difference was also found to be exacerbated when the 
base of support was unstable (Flanagan, May & Dobie, 2004a; Flanagan, May & 
Dobie, 2004b; Stoffregen, Bardy, Merhi & Ouillier, 1994).  Furthermore, PI has 
been found to be greater on motion platforms when visual information about the 
relative motion of platform and the static world is removed (Dobie, May & 
Flanagan, 2003).  However, these studies failed to address the factor of sex as 
possibly contributing to these postural measures.  While other researchers have 
reported another difference in posture having to do with men and women 
exposed to similar types of dynamic motion environments, these differences 
have been traditionally discussed in terms of physical sex differences having to 
do with body type (i.e., height, weight, muscle tone) (Larsen, et al, 1998; Lyons, 
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1992).   In addition, some studies have failed to find significant sex differences in 
PI, even in posturally challenging environments (Owen, Leadbetter & Yardley, 
1998).  However, this study failed to look at the factor of hormonal fluctuations 
which might be another important factor influencing the data.   
Recent research conducted by Fridén, et al (2003) suggests that postural 
differences such as these may be linked to hormonal fluctuations, which co-occur 
with phases of the female menstrual cycle.  Their study measured balance in 13 
healthy women at three times during two concurrent menstrual cycles.  They first 
tested participants during the early follicular phase, day 3-5 of their cycle.  The 
second test occurred during the ovulatory phase, detected by luteinizing 
hormone surge identified in blood samples (around day 11-14 of their cycle).  
The final test session was during the mid-luteal phase, seven days after each 
participant’s ovulatory phase.  Postural sway was measured in terms of ankle 
disc movement recorded while balancing on the dominant leg, and knee-joint 
kinesthesia in terms of reported perception of exogenous knee flexion/extension 
while blindfolded.  In addition, these researchers also measured ratings of 
premenstrual syndrome by way of a Cyclicity Diagnoser scale (consisting of 
mood, somatic, social, and occupational parameters), which was completed 
every day throughout the experimental period.  These symptoms were examined 
for an increase in at least 3 negative symptoms during 9 premenstrual days as 
compared to 9 mid-follicular days.  As may be expected, this study revealed an 
increased incidence of physical symptoms in participants, particularly during the 
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permenstrual phase (early follicular phase) and premenstrual phase (mid-luteal 
phase).   
Of interest however, this study found that balance measures revealed both 
significantly higher levels of postural sway as well as knee-joint kinesthesia in 
women classified as having premenstrual syndrome (Fridén, et al, 2003).  There 
was also an effect of phase elicited upon PI, with an increase in postural sway 
during the early follicular period, for both women with and without premenstrual 
syndrome, as well as an interaction of phase with premenstrual syndrome 
classification, with the highest levels of postural sway found with premenstrual 
syndrome subjects during the mid-luteal phase.  These findings were discussed 
by the researchers in terms of the positive relationship between levels of 
estrogen and postural stability measures in women.  However, the sequence of 
their experimental sessions was not counterbalanced.  Therefore, these data 
may be compromised, as there may be an influence of motor learning upon this 
measure.   
In addition, as mentioned previously, research in sports medicine has also 
revealed significant sex differences in the rates of sports related injuries, with 
women sustaining far more knee injuries than men (Hewett, 2000).  Studies have 
implicated female reproductive hormones, such as estrogen, as influencing the 
female neuromuscular system (Chandy & Grana, 1985; Huston & Wojtys, 1996; 
Zelisko, Noble & Porter, 1982; Haycock & Gillette, 1976).  Levels of estrogen 
have been found to be positively related to muscle fatigue, as well as negatively 
related to ligament strength and speed of muscle relaxation (Booth & Tipton, 
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1970; Sarwar, Beltran & Rutherford, 1996).  Estrogen exerts it’s influence on 
neuromuscular systems indirectly via its effects on sport performance (Lebrun, 
1994; Lebrun, 1993), with decreased skill performance found in women during 
the mid-luteal phase (Posthuma, et al, 1987) and decreased injury rates during 
the permenstrual phase (Wojtys, et al, 1998; Myklebust, et al, 1998).  By 
stabilizing reproductive hormone levels to prevent the ovulatory surge, findings 
such as these appear to diminish when oral contraceptives are utilized (Moller-
Nielson J, Hammar, 1989; Moller-Nielson J, Hammar, 1991).  These studies 
have vast implications to the influence of hormonal fluctuation upon other 
measures of PI. 
There are a number of factors that have yet to be addressed in the area of 
PI.  For instance, endocrine studies have not addressed the issue of postural 
response to additional challenges, such as dynamic or virtual motion 
environments.  In addition, kinesiology studies that have utilized virtual motion 
environments have similarly failed to address the factor of hormonal fluctuations, 
which may also be instrumental in behavioral responses, such as PI.  Once 
again, these studies underscore the need to clarify the factors contributing to sex 
differences in PI.  Again, questions remain as to whether these findings are 
attributable to menstrual phases, body type, or to a combination of these factors. 
 
Experimental Rationale 
The intent of this investigation was to determine whether exposure to 
virtual motion environments, during various phases of the menstrual cycle 
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(premenstrual, permenstrual, ovulation) would reveal sex differences in postural 
stability and MS during some phases, but not others.  Two experiments were 
conducted to assess these postulates.  The first experiment looked at baseline 
symptoms of discomfort, removed from specific motion exposure.  This study 
involved men and women asked to fill out daily living logs for a period of 40 days, 
in order to provide a baseline for any symptoms later elicited upon exposure to 
motion related activity.  In addition, this study examined both the sex of the 
participant and phase (premenstrual, permenstrual, ovulation) differences in 
these data.  The second experiment looked at the influence of sex and phase 
upon postural and symptom measures in response to exposure to visually 
depicted motion stimulation within the laboratory environment.  This experiment 
involved asking male and female participants to view a rotating Archimede’s 
spiral for a maximum duration of twenty minutes.  Exposures were timed to place 
each woman in each of the three previously mentioned phases of her menstrual 
cycle (the men exposed by yoking their exposure time to a female counterpart) 
as the factors of sex and phase were examined in reference to their effects upon 
various measures of motion perception.  The results of this investigation will 
reveal whether previous experimental attempts to support reported sex 
differences in MS and PI are dependent upon what phase of the menstrual cycle 
women are experiencing when exposed to provocative motion stimulation.    
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CHAPTER II:  METHODS 
 
Experiment 1 
The aim of this study was to gather information that might be useful in 
generating answers to questions regarding the relationship between sex and 
phase of the female menstrual cycle and different aspects of daily living, 
specifically daily activities, feelings of wellness and discomfort, and consumption 
habits.  We utilized Daily Living Logs (DLL’s) to attempt to determine if 
fluctuations in these three factors varied as a function of sex and phase of the 
menstrual cycle.   
 
 Participants 
24 university students served as participants.  Men and women ages 18-
40 years were included.  This population was used because it was representative 
of the young adult population, within their reproductive phase of life, which we 
wished to study.  Effect sizes from previous studies were computed to determine 
the minimum sample size necessary to produce a significant effect with a power 
of 0.80 (Keppel, 1991).  However, these effect sizes were viewed as 
conservative estimates of the variability in DLL responses that were expected in 
participants in the proposed investigation.  The sample number proposed was 
based upon the results of a study conducted by Dobie et al. (2001), which 
indicated significant sex differences in motion sickness history in both youth and 
young adult populations, with F (1, 437) = 31.83, p < 0.0001, and an effect size 
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computed as 0.210 for the youth population, and F (1, 475) = 6.91, p < 0.009, 
and an effect size computed as 0.130.  The proposed investigation involved 
repeated measures of symptoms of distress, which was hypothesized to elicit a 
stronger effect than that elicited by a single sample from a given population.   
Access to population was gained through undergraduate classes at UNO.  
Participation was limited to classes whose instructors allow extra credit for 
participation.  Consent for callback was obtained from a brief medical 
questionnaire (see Appendix) completed by the subject through his or her 
undergraduate course.  Participation in this experiment was limited to those 
students who report no history of visual or vestibular impairments, epilepsy, 
current pregnancy, or recent illness, and were in their usual state of health 
according to self-report on the medical history questionnaire.  Consent (see 
Appendix) was obtained from each participant immediately prior to the onset of 
his or her participation in the study.   Approval for this portion of the study was 
obtained from the University of New Orleans’ All University Committee on the 
Use of Human Subjects (see Appendix). 
 
 General Experimental Procedures 
The initial phase of this experiment utilized a brief medical questionnaire 
(see Appendix)  to select a sample of self-reported healthy subjects.   Those 
healthy individuals interested in participating further were then invited to take part 
in the second phase of the study.  Consent was obtained from each participant 
with the appropriate written consent form (see Appendix) prior to beginning the 
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second phase of the study, in which they were asked to complete a series of 
DLL’s (see Appendix) each day, over the course of the following calendar month.   
DLL’s were used for participants to indicate certain aspects of their 
activities of daily living, once a day for the following forty days.  The DLL’s 
consisted of three parts, the first part an activities checklist; the second part, a 
consumption checklist; the third part, a symptom checklist.  The design of the 
DLL’s was based upon previous studies conducted by Dobie, et al (2001), 
looking at variables such as activities and motion sickness history in student 
populations, and a study by Weller and Weller (2002), which investigated 
symptoms of discomfort related to the female menstrual cycle.  Students were 
instructed to return the completed forms to the project director every day, by 
submitting a paper log in person on a daily basis, or by completing and 
submitting their logs online.  The online questionnaires were posted on our 
laboratory website, and interested students were instructed how to utilize this 
means of participation.  The results of each online questionnaire submitted were 
then forwarded to our laboratory’s email account on a daily basis.  Responses 
were submitted under the heading of a code, which the participants individually 
selected in the laboratory, and were confidential.  The importance of timeliness 
was emphasized to each of the participants, in addition to the fact that they could 
withdraw their consent and halt their participation in this study at any time, if they 
should so request.  Participants were treated in accordance with the “Ethical 
Principles of Psychologists and Code of Conduct”  (American Psychological 
Association, 1992).     
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A 3 x 2 x 3 factorial, mixed repeated measures design was used.  The first 
independent variable, a within subjects variable, was phase of the month 
(phase/trial).  Responses of both men and women were grouped into three 
sections.  The sorting of these three samples was related to specific phases of 
the female menstrual cycle, consisting of: early follicular phase (eFP); ovulatory 
phase (OP); mid-luteal phase (mLP).  The exact timing of these was based upon 
the average length of the female menstrual cycle (28 days), and the average time 
during which these three phases tend to occur.  For example, eFP was 
established between days 2-5, OP was set between days 11-14, and mLP 
encompassed days 18-21 of cycle (Fridén, et al, 2003; Grunfeld, et al, 1998; 
Grunfeld & Gresty, 1998; Neal, 2002).   Female participants’ menstrual cycles 
were normalized to the 28 day cycle, and the sampling periods were taken based 
upon these normalized cycles.  The responses from the male participants were 
grouped by yoking their data to a female counterpart  [i.e., yoked to eFP of 
matched female (~ eFP); yoked to OP of matched female (~ OP);  yoked to mLP 
of matched female (~ mLP)].   
 The second independent variable, a between subject factor, was the sex 
group of the participants (either male or female).  The final independent variable, 
a within subjects factor, was sequence.  Participants completed the DLL’s at 
three different times of their cycle, with some completing the DLL’s first during 
eFP/~eFP (sequence 1), some during OP/~OP (sequence 2), and some 
beginning during mLP/~mLP (sequence 3).   
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Three dependent variables were measured:  sum of the activities 
checklist; sum of the consumption checklist; and sum of the daily symptom 
checklist (see Table 1 below).  However, the main variable of interest was the 
symptom checklist, to examine how MS symptoms changed over the cycle to 
determine how much contamination occurred in MS measures in the following 
experiment.   
 
Table 1.  Experiment 1: Dependent Measures 
 Variable Measures 
Daily 
Activities 
Sum of Activities 
Checklist  
Daily 
Consumption 
Sum of 
Consumption 
Checklist 
Daily 
Symptoms 
Sum of Symptom 
Checklist 
 
 
 
Experimental Hypotheses  
1. A significant main effect of sex of the individual [sex group] upon all three DLL 
measures;  
2. A significant main effect of phase of the menstrual cycle [phase/trial] upon all 
three DLL measures in the group of women alone;  
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3. A significant interaction effect of sex group and phase/trial upon all three DLL 
measures; and  
4. No significant effect of sequence upon any of the three DLL measures. 
 
Experiment 2 
The aim of this study was to gather information that might be useful in 
generating answers to questions regarding the relationship between phases of 
the female menstrual cycle, posture, and feelings of well being.   
 
 Participants 
24 university students (6 men) served as participants.  Men and women 
ages 18-30 were included.  This population was used because it was 
representative of the young adult population within their reproductive phase of 
life, which we wished to study.  Effect sizes of previous studies have been 
computed to determine the minimum sample size necessary to produce a 
significant effect with a power of 0.80 (Keppel, 1991).  However, these effect 
sizes were viewed as conservative estimates of the variability in MS and PI 
responses that might be expected in participants in the proposed investigation.  
The sample number proposed was based upon the results of three studies: a 
study conducted by Flanagan, et al. (2004a), which indicated significant 
differences in PI and MS in a sample of 8 young adults exposed to visual motion 
stimulation, with F (1, 8) = 13.33, p < 0.01, with an effect size computed as 0.743 
(see Figure 1), and with F (2, 7) = 40.57, p < 0.001, with an effect size computed 
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as 0.903 for MS; a study conducted by Grunfeld, et al (1998), which found a 
significant effect of sex and menstrual phase upon MS in women exposed to 
prolonged periods of ship motion, with F (2, 15) = 50.38, p < 0.001, with an effect 
size computed as 0.870; and a study conducted by Fridén, et al (2003), which 
indicated a significant effect of menstrual phases upon symptoms of discomfort 
and PI measures in a sample of 8 women.  The current study involved repeated 
measures of symptoms of distress, MS, and PI, which were hypothesized to elicit 
a stronger effect than those elicited by a single sample from a given population.   
Access to population was again gained through undergraduate classes at 
UNO.  Participation was limited to classes whose instructors allow extra credit for 
participation.  Consent for callback was obtained from a brief medical 
questionnaire (see Appendix) completed by the subject through his or her 
undergraduate course.  Participation in this experiment was similarly limited to 
those students who reported no history of visual or vestibular impairments, 
epilepsy, current pregnancy, or recent illness, and were in their usual state of 
health according to self-report on the medical history questionnaire.  In addition, 
female participants were also restricted to those reporting normal menstrual 
cycles, and those not currently taking any form of hormonal contraceptive within 
three months of their participation in this study.  Consent (see Appendix) was 
obtained from each participant immediately prior to the onset of his or her 
participation in the study.  These participants were also asked to refrain from 
consuming alcoholic beverages or taking medications for the 24-hour period 
preceding the experiment.  In addition, subjects were asked to reschedule their 
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session within a three day period, if they felt that they were not in their usual 
state of fitness.  Once again, all information was confidential and participants 
were treated in accordance with the “Ethical Principles of Psychologists and 
Code of Conduct”  (American Psychological Association, 1992).  Approval for this 
portion of the study was obtained from the University of New Orleans’ All 
University Committee on the Use of Human Subjects (see Appendix). 
 
General Experimental Procedures 
After obtaining informed consent, height (cm) and weight (kg) of subjects 
were measured and recorded as possible covariates.  Subjects were asked to 
participate barefoot and to wear a safety helmet during each session.   
A 3 x 2 x 3 factorial, mixed repeated measures design was used.  
Participants were instructed to stand between a pair of handlebars with their feet 
30.5 cm apart, at a distance of 45.75 cm from a viewing screen with both feet 
firmly planted on the floor.  Participants were instructed to look towards this 
screen, upon which an image of a rotating spiral was rear projected, and to stand 
in an upright posture during all experimental conditions, but to grab the 
handlebars if they began to feel unsteady.  The image projected, which was 
viewed binocularly, consisted of alternating light and dark spirals (with luminance 
values of 1.2 and 5.7 candles per meter squared, and a contrast value of 38%) 
projected onto the viewing screen, an Archimede’s spiral rotating at 10 rpm, 
subtended 95° of visual angle presented for a maximum duration of twenty 
minutes.   
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The first independent variable, a within subjects variable, was testing 
phase/trial.   Both men and women were tested three times.  The timing of these 
sessions was related to specific phases of the female menstrual cycle.  
Exposures were timed to place each woman in specific phases of her menstrual 
cycle.  These consisted of: early follicular phase (eFP); ovulatory phase (OP); 
mid-luteal phase (mLP).   
Once again, the exact timing of these sessions was based upon the 
average length of the female menstrual cycle (28 days), and the average time 
during which these three phases tend to occur.  For example, eFP was 
established between days 2-5, OP was set between days 11-14, and mLP 
encompassed days 18-21 of cycle (Fridén, et al, 2003; Grunfeld, et al, 1998; 
Grunfeld & Gresty, 1998; Neal, 2002).   Female participants’ menstrual cycles 
were normalized to the 28 day cycle, and the sampling periods were taken based 
upon these normalized cycles.  Men were exposed to the provocative stimulus by 
yoking their exposure time to a female counterpart [i.e., yoked to eFP of matched 
female (~ eFP); yoked to OP of matched female (~ OP); yoked to mLP of 
matched female (~ mLP)].   
The timing of each of the three phases of female participants’ menstrual 
cycles were estimated for the purpose of scheduling each of their experimental 
sessions.  As mentioned previously, these sessions were scheduled to expose 
women to the motion stimulus during: menstruation (2 to 5 days after the onset of 
their cycle); ovulation (13 to 15 days prior to the predicted onset of their next 
cycle); and in the mid-luteal phase (6 to 8 days prior to the predicted onset of 
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their next cycle).  The predicted onset dates were derived by the average lengths 
of each participant’s last two cycles and projecting that average to the future 
cycle.  The actual onset date was subsequently noted during the experimental 
sessions, with any modifications to future sessions being made in response to 
the new average length of the participant’s menstrual cycle. 
As mentioned previously, while reproductive hormones may be measured 
in a number of different manners of both sampling and processing methodology 
(Snowden & Ziegler, 2000), routine means of measuring hormone levels, such as 
via blood and urine samples, were not utilized because of the cost and 
inconvenience involved in this type of method of hormone assessment.  Saliva 
sampling has been shown to have the advantages of being non-invasive, as well 
as easy to collect and handle, and been found to correlate well with free levels of 
circulating hormones.  Estradiol, a hormone readily sampled through saliva, has 
been found to be a highly physiologically active form of estrogen readily available 
for analysis of estrogen levels in female subjects (Becker, et al, 2004; Gill, 1985).   
In that estradiol may be easily measured by way of salivary hormone 
assessments (Ilya, McLure & Farhat, 1999; Vuorento & Huhtaniemi, 1992), which 
also has the attribute of being able to be conveniently stored for long periods of 
time in a cool environment, hormone levels were assessed in this manner, to 
confirm that sessions were testing female participants during the appropriate time 
of their menstrual cycle.  Saliva samples were collected prior to each 
experimental session from each of the female participants.  Saliva was collected 
by way of a passive drool method, which involved the women drooling saliva into 
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a 2.0 milliliter cryovial.  These vials were subsequently stored in a –20°C freezer 
until data collection was complete.  Saliva samples for the OP and mLP sessions 
were then transported in dry ice, to Salimetrics, LLC for analysis of salivary 
estradiol levels by enzyme immunoassay.  Salimetrics reports the minimal 
concentration of estradiol that can be distinguished is 1.0 pg/mL; the magnitude 
of the saliva-serum correlation, r (18) =0.71, p < 0.001.  These analyses were 
specific and sensitive to the low levels of hormones normally found in this type of 
sampling technique.  Further data analysis was then limited to those women 
whose salivary estradiol analyses confirmed that they were tested at the 
appropriate time of their menstrual cycle. 
 The second and third independent variables, between subject factors, 
were sex group of the participants (men or women) and sequence of conditions.  
The sequence of exposure was partially counterbalanced across subjects (see 
Table 2 below). with a third of the participants experiencing their first session 
during eFP/~eFP (sequence 1), a third experiencing their first session during 
OP/~OP (sequence 2), and the remaining third experiencing their first session 
during mLP/~mLP (sequence 3).   
Four dependent variables were measured simultaneously during each 
experimental session: illusory motion perception, head movement, body 
movement, and motion sickness (MS) (see Table 3 below).  Prior to each 
session, subjects were instructed to stand with their eyes closed for five seconds, 
and then with their eyes open viewing a blank viewing screen for five seconds, 
while baseline measures of head movement, body movement, illusory motion 
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perception, and MS were recorded.  Subjects were then instructed to close their 
eyes while the stimulus was being initiated, told to open their eyes with the onset 
of rotation of the Archimede’s spiral.   
Head movement was measured by way of an electromagnetic, six-degree-
of-freedom, tracking device (3SPACE: InsideTRAK by Polhemus).  A transmitter 
was placed on top of the participant’s safety helmet, and a receiver placed 9.5 
inches (24.13 cm) immediately above the subject’s head.  Signals indicative of  
 
Table 2.  Experiment 2: Partial Counterbalancing of Experimental Conditions 
Sequence 
# Female Subjects Male Subjects 1
st  2nd  3rd  
1 
E2W-4, E2W-7,  
E2W-10*, E2W-13*,  
E2W-16*, E2W-23 
E2M-4, E2M-7 
  eFP 
~eFP 
  OP 
~OP 
  mLP 
~mLP 
2 
 
E2W-2, E2W-5*,  
E2W-11, E2W-14,  
E2W-17*, E2W-21  
E2M-5, E2M-8  
  OP 
~OP 
  mLP 
~mLP 
  eFP 
~eFP 
3 
 
E2W-3, E2W-12*,  
E2W-15, E2W-18*,  
E2W-19, E2W-24 
E2M-3, E2M-6 
  mLP 
~mLP 
  eFP 
~eFP 
  OP 
~OP 
 
eFP: early follicular phase    ~ eFP: yoked to eFP of matched female 
OP: ovulatory phase    ~ OP: yoked to OP of matched female 
mLP: mid luteal phase    ~ mLP: yoked to mLP of matched female 
* Salivary Estradiol Levels Confirmed Timing of OP and mLP 
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displacement of the transmitter in reference to the receiver were relayed, 
collected, and recorded on a Base 386 computer.   These measures were taken 
once every other minute for a duration of 8 seconds, at a sampling frequency of 
50 Hz.  Variance of linear movements of the participant’s head (surge and sway) 
recorded over the course of each experimental session, and the latency to the 
onset of these two movements entailed four measures of head movement (see 
Table 3). 
Body movement was measured by way of an AMTI AccuSway force plate 
platform (4.4 cm in height by 50 cm2).  Similar to head movement, these  
 
 
Table 3.  Experiment 2: Dependent Measures 
 Variable Measures 
Illusory 
Motion 
Perception  
Latency to 
onset of Illusory 
motion 
perception 
Duration of 
Illusory motion 
perception  
Magnitude of 
perceived 
surge 
Magnitude 
of perceived 
sway 
Head 
Movement  
Variance of linear surge 
head movement 
Variance of linear sway  
head movement 
Body 
Movement 
Variance in 
center of 
pressure 
Mean velocity 
of center of 
pressure 
Length of 
sway path 
Area of 
sway path 
Motion 
Sickness 
(MS) 
Tolerance for 
stimulation 
Magnitude ratings of 
MS 
Difference Score 
of Symptom 
Checklist 
 
 32
measures were taken once every other minute for a duration of 8 seconds, at a 
sampling frequency of 50 Hz.  Variance in center of pressure, mean velocity of 
center of pressure, length and area of sway path recorded over the course of 
each experimental session entailed four measures of body movement (see  
Table 3). 
MS was measured by way of magnitude ratings (scale of 0 = none, to 10 = 
maximum) of feelings of motion sickness verbally obtained from the subject once 
every minute for the 20 minute maximum duration of each experimental session.  
This term was verbally described to the subjects by the experimenter as any 
feelings of discomfort.  The maximum magnitude rating of motion sickness 
constituted one measure of MS.  In addition, MS was also assessed by way of 
the amount of time the participant was willing to endure exposure to the 
experimental stimulus (tolerance time), as well as the difference score between 
the symptom checklist completed after minus the symptom checklist completed 
before the experimental session (see Table 3).   
 
Experimental Hypotheses 
1. A significant main effect of sex group upon all MS measures; 
2. A significant main effect of phase/trial upon all MS measures in the group 
women alone;  
3. A significant interaction effect of sex group and phase/trial upon all MS 
measures;  
4. No significant effect of sequence upon any of the MS measures; 
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5. A significant main effect of sex group upon all PI measures;  
6. A significant main effect of phase/trial upon all PI measures in the group of 
women alone;  
7. A significant interaction of sex group and phase/trial upon all PI measures;  
8. No significant effect of sequence upon any of the PI measures. 
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CHAPTER III: RESULTS 
 
All analyses were performed using SPSS for Windows (version 11.5).  The 
dependent variables were submitted to multivariate analysis of variance, as well 
as multiple analyses of variance separately conducted on each dependent 
variable, to determine any significant differences in DLL’s, MS, or PI existing 
between the independent variables over the three experimental conditions.  
Tests subsequent to analysis of variance were employed as appropriate.   
 
Experiment 1 
A total of 80 individual participants submitted 1,608 DLL’s (58 paper logs) 
over the course of the fall and spring semesters.  The following analyses utilized 
data only from those surveys completed by the 32 participants (27 women) who 
completed a series of at least 40 DLL’s.  Table 4 shows a summary of some of 
the descriptive and demographic data regarding these participants. 
As mentioned previously, DLL submissions were sorted into three phases, 
correlating with different periods of the female menstrual cycle.  The exact timing 
of these were based upon the average length of the female menstrual cycle (28 
days), and the average time during which these three phases tended to occur.  
Each female participant’s menstrual cycle was normalized to the 28 day cycle, 
and the sampling periods were taken based upon the normalized cycle.  For 
example, eFP was established between days 2-5, OP was set between days 11-
14, and mLP encompassed days 18-21 of cycle (Fridén, et al, 2003; Grunfeld, et 
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al, 1998; Grunfeld & Gresty, 1998; Neal, 2002).  The responses from the male 
participants were grouped by yoking their data to a female counterpart  [i.e., 
yoked to eFP of matched female (~ eFP); yoked to OP of matched female (~ 
OP);  yoked to mLP of matched female (~ mLP)].  In addition, as five of the 
female participants failed to indicate either menstrual cramping or bleeding on 
any of their 40 DLL’s, these data were coded as a separate group, labeled 
Menses Not Specified (MNS), for the analyses of the entire group of participants 
(men, women and MNS), and were not used in the analysis of the group of 
women alone. 
 
Table 4.   Experiment 1: Descriptive Summary of Participants by Sex Group 
 
  Women  Women  Men 
     MNS 
 
Sample Size   N (%) 22 (68.9) 5 (15.6) 5 (15.6) 
 
Age  Mean (SD) 20.5 (3.5) 20.2 (2.5) 22.4 (4.8) 
 
Race  N (%) 
 Asian 2   (9.1) 0  0 
 Black 3 (13.6) 0  0 
 Hispanic 1   (4.5) 5 (100) 5 (100) 
 White 6 (72.7) 0  0  
 
Sequence N (%) 
1.  eLP-OP-mLP  7 (31.8)  MNS NA 
2.  OP-mLP-eLP 9 (40.9) 
3.  mLP- eLP-OP  5 (22.7)  
 
Length  Mean (SD)  28.2 (6.5) MNS NA   
Menstrual  
Cycle  
 
  MNS : Menses Not Specified   NA: Not Applicable 
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Data for each subject were reduced by generating the sum of each 
measure for the four day period that encompassed each of the three phases.  In 
addition, the sum of the activity checklist excluded the number of hours spent 
sleeping, which was analyzed separately, as this was considered an indication of 
a more passive measure of lethargy, rather than activity.  Therefore, a total of 
four measures were analyzed to evaluate any significant effects of sex group, 
phase/trial or sequence. 
 
Daily Activities Checklist 
 Sum of the Daily Activity Data are shown in Table 5.  Analysis of variance  
of the sum of the activities failed to reveal a significant main effect of sex group 
 
Table 5.  Experiment 1: Sum of Daily Activity Data (4 days) 
 
Group                      Phase/Trial  
                      Mean (SD)  
 
 
Women  eFP/~eFP OP/~OP mLP/~mLP 
 
Menses Specified 69.2 (21.1) 68.9 (18.3) 73.3 (23.5) 
 
Menses Not Specified 76.6 (24.4) 70.2 (18.2) 75.6 (18.0) 
 
Men  71.2 (21.2) 75.2 (18.3) 73.8 (12.5) 
    
 
 
Italicized scores based upon data from days 2-5, 11-14, 18-21, as these subjects made no report 
of menstrual bleeding, either because it was not specifically reported or it was not applicable. 
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 or phase/trial, nor any significant interaction of these two variables.  In addition, 
analyses also failed to reveal any significant effect of sequence, neither in 
women alone, nor in the entire participant group as a whole.   
 
Sleep 
Mean number of hours of sleep for the different experimental phases are 
shown in Table 6 below.  Analyses for this measure were performed only for the 
data from the 30 participants who reported sleep data for all three phases.   
Analysis of variance of sleep failed to reveal a significant main effect of sex 
group, phase/trial or sequence, neither in women alone, nor in the entire 
participant group as a whole.   
  
Table 6.  Experiment 1: Mean Hours of Sleep (4 days) 
 
Group                      Phase/Trial  
                      Mean (SD)  
 
 
Women  eFP/~eFP OP/~OP mLP/~mLP 
 
Menses Specified 6.93 (2.26) 7.04 (2.69) 7.44 (2.56) 
 
Menses Not Specified 6.25 (1.99) 6.65 (1.22) 7.10 (0.68)  
 
Men  7.25 (2.26) 7.38 (1.58) 6.98 (2.07) 
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Daily Consumption Checklist  
Sum of the Daily Consumption Checklist for the different experimental 
phases are shown in Table 7 below.  As Mauchly’s test of sphericity of these data 
revealed a significant effect of phase/trials, for the entire group [Mauchly’s W = 
0.753, p < 0.025] as well as for women alone [Mauchly’s W = 0.477, p < 0.001], 
the Greenhouse-Geisser factor was subsequently used to correct for this effect.  
However, analysis of variance of Daily Consumption data failed to reveal a 
significant main effect of sex group, phase/trials or sequence, neither in women 
alone, nor in the entire participant group as a whole.   
 
Table 7.   Experiment 1: Sum of Daily Consumption Data (4 days) 
 
Group                      Phase/Trial  
                      Mean (SD)  
 
 
Women  eFP/~eFP OP/~OP mLP/~mLP 
 
Menses Specified 22.23 (25.7) 18.27 (18.8)  19.05 (22.2) 
 
Menses Not Specified 26.0 (37.5)  28.4 (38.6)  27.2 (47.6)  
 
Men  14.2 (12.9)  15.0 (11.4)   13.4 (8.23) 
    
 
 
Daily Symptom Checklist 
Sum of the Daily Symptom Checklist for the different experimental phases 
are shown in Table 8 below.  Once again, as Mauchly’s test of sphericity of these 
data revealed a significant effect of phase/trials, for the entire group [Mauchly’s 
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W = 0.606, p < 0.001] as well as for women alone [Mauchly’s W = 0.531, p < 
0.003], the Greenhouse-Geisser factor was subsequently used to correct for this 
effect.  Analysis of variance of Daily Consumption data failed to reveal a 
significant main effect of sex or sequence, neither in women alone, nor in the 
entire participant group as a whole.   
While there was not a statistically significant effect of phase upon this 
measure [F (2, 34.268) = 2.904, p < 0.090, eta 0.133, power 0.432], Figure 1 
reveals greater amounts of symptomatology apparent in women during the 
eFP/~eFP phase as opposed to the oP and mLP phase conditions.  These 
findings indicate that this analysis might be able to attain levels of significance 
with a larger sample size.   
 
Table 8.  Experiment 1: Sum of Daily Symptom Data (4 days) 
 
Group                      Phase/Trial  
                      Mean (SD)  
 
Women  eFP/~eFP OP/~OP mLP/~mLP 
 
Menses Specified 53.2 (38.0) 37.0 (33.9) 38.4 (27.7) 
 
Menses Not Specified 31.4 (10.6)  26.4 (8.47)  21.8 (13.5) 
 
Men  28.0 (14.7)  26.4 (10.0)  21.0 (8.28) 
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Figure 1.  Sum of four day periods of daily symptom ratings of female 
participants plotted as a function of phase of the female menstrual cycle.  In this 
and subsequent figures, vertical error bars represent 1± SE.   
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Experiment 2 
Of the thirty-two individuals (eight men) who began participation in the 
second portion of this study, only 24 subjects (6 men) completed all three 
experimental sessions.  Once again, these sessions were partially 
counterbalanced to control for an effect of sequence (see Table 2 discussed 
previously).  All measures of each of the dependent variables (see Table 3 
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discussed previously) underwent Analyses of Variance. These data were sorted 
into three groups based upon two factors: sex and salivary estradiol levels.  One 
group consisted of all 6 male participants; a second group was limited to those 
female subjects whose salivary estradiol levels confirmed that they were tested 
during the appropriate time of their menstrual cycle, to test during OP and mLP 
[group of women with phases confirmed (C)], and the third group consisted of 
those female subjects whose salivary estradiol levels failed to confirm that they 
were tested during the appropriate time of their menstrual cycle [group of women 
with phases unconfirmed (U)].   
Examination of the results of salivary estradiol samples revealed that only 
seven of the eighteen women had hormone levels confirming that they were in 
fact tested at the appropriate time to sample the target phases of their menstrual 
cycles, with low levels of salivary estradiol during the mid-luteal phase, and 
higher levels during the ovulatory phase.  See Table 9 for levels of salivary 
 
Table 9.  Experiment 2: Women Participants Salivary Estradiol Levels 
 
Group             Salivary Estradiol (pg/ml)  
                      Mean (SD)  
 
 
Women  OP/~OP mLP/~mLP 
 
Phases Confirmed (C) 11.8 (4.50) 7.37 (3.63) 
 
Phases Not Confirmed (U) 8.78 (2.53) 11.05 (1.66) 
 
Samples Insufficient 36.4 (53.9) 13.69 (6.70) 
Or Contaminated 
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Table 10.  Experiment 2: Summary Descriptive Data of Participants  
 
  Women  Women  Men 
  Phases Phases 
  Confirmed Unconfirmed 
 
Sample Size   N 7 11   6  
 
Age  Mean (SD) 20.3 (1.98) 21.9 (3.91) 25.8 (7.52) 
 
Height (cm) Mean (SD) 165.4 (4.70) 162.5 (7.12) 180.9 (6.98) 
 
Weight (kg) Mean (SD) 66.8 (9.55) 62.2 (16.0) 84.72 (15.4) 
 
Race  N  
 Asian 0   2   0 
 Black 1 0   1 
 Hispanic 1 1   0  
 White 5 8   5  
Sequence N 
1.  eLP-OP-mLP  3  3   2 
2.  OP-mLP-eLP 2 4   2 
3.  mLP-eLP-OP  2 4   2 
 
 
Length  Mean (SD)  27.2 (2.79) 29.6 (3.26) NA   
Menstrual  
Cycle  
 
 
estradiol present in the female participants, and Table 10 for a summary of 
demographic data and group membership.  Further analysis of the data was 
restricted to two groups: men and women with confirmed menstrual phases.   
Lastly, as the results of Experiment 1 revealed no statistically significant 
effect of sex or phase upon any single dependent variable, there was no need 
subtract the influence of these variables from the data gathered in Experiment 2.   
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Illusory Motion Data 
 
1. Latency Time 
Latency times to the report of illusory motion are shown in Table 11.  As 
Mauchly’s test of sphericity of these data revealed a significant effect of repeated 
trials, for analysis of both groups [Mauchly’s W = 0.020, p < 0.001], as well as for 
the analysis of the group of women with confirmed (C) phases alone [Mauchly’s 
W = 0.005, p < 0.001], the Greenhouse-Geisser factor was subsequently used to 
correct for this effect.  However, analysis of variance of this measure failed to 
reveal a significant main effect of sex group, phase/trial, or sequence, nor any 
significant interaction of these variables, in analyses of the group of women 
alone, nor between both groups of participants.   
 
Table 11.  Experiment 2: Illusory Motion Data: Latency to Onset of Illusory 
Motion   
 
Group                                    Latency to Onset of Illusory Motion (seconds)  
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women (C) 18.4 (5.7) 19.4 (7.2)  189.9 (168.4) 
 
Men  244.2 (191.3) 263.8 (188.5)     253.3 (189.8) 
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2. Duration 
Duration times of the report of illusory motion are shown in Table 12.  
Once again, as Mauchly’s test of sphericity of these data revealed a significant 
effect of repeated trials, for analysis of both groups [Mauchly’s W = 0.026, p < 
0.001] as well as for the group of women alone [Mauchly’s W = 0.008, p < 0.001], 
the Greenhouse-Geisser factor was subsequently used to correct for this effect.  
However, again, analysis of variance of this measure failed to reveal a significant 
main effect of sex group, phase/trial, or sequence, nor any significant interaction 
of these variables, in analyses of the group of women, nor of both groups of 
participants viewed together.   
 
Table 12.  Experiment 2: Illusory Motion Data: Duration of Illusory Motion 
 
Group                                         Duration of Illusory Motion (seconds)  
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C) 1181.6 (5.7) 1180.6 (7.2) 981.6 (166.9) 
 
Men  955.8 (191.3) 936.2 (188.5) 946.7 (189.8) 
 
 
3. Magnitude of Perceived Surge 
Magnitude of perceived surge data are shown in Table 13.  Mauchly’s test 
of sphericity showed no significant effects of repeated measures on these 
measures, neither in the split analysis of the C group of women alone, nor in the  
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Table 13.  Experiment 2: Illusory Motion Data: Magnitude of Perceived Surge 
 
Group                                                Magnitude of Surge  
  (0 to 10, none to maximum) 
                Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women (C)   
- maximum rating  5.14 (1.10) 4.29 (1.02) 4.00 (1.05) 
- final rating 3.71 (1.02) 2.29 (0.81) 3.29 (1.17) 
 
Men 
- maximum rating  3.50 (0.99) 1.50 (0.81) 1.67 (0.84) 
- final rating 1.00 (0.63) 1.17 (0.79)  0.67 (0.49) 
 
 
 
analysis of both groups of participants viewed together.  Analysis of variance of 
these measures revealed a significant effect of phase/trials upon the measure of 
maximum magnitude rating of perceived surge [F (2, 14) = 4.020, p < 0.042, eta 
0.365, power 0.618] within both groups of participants.  Figure 2 shows the 
increased magnitude ratings of perceived surge elicited in during the initial period 
(eFP/~eFP) as compared to the two other phases.  Post hoc analyses reveal 
these differences to lie specifically between the eFP/~eFP condition, and the 
other two phase/trial conditions, with Tukey’s p < .028.  .Analysis of this group of 
data failed to reveal any further effects of sex group or sequence.   
While there was not a statistically significant main effect of phase/trials  
upon the measure of maximum magnitude rating of perceived surge in the 
analyses of women alone, the data appear to be approaching levels of 
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significance [F (2, 8) = 3.714,p < 0.072, eta 0.481, power 0.509].  Figure 3 shows 
the increased magnitude ratings of perceived surge elicited in women during the 
early follicular period as compared to the two other phases.  Women report a 
stronger perception of forward/backwards motion when they are menstruating as 
opposed to the two other experimental phases.  
 In addition, while analysis of the women alone failed to reveal a significant 
main effect of sequence upon either of these measures, there was a significant 
 
Figure 2.  Maximum magnitude rating of perceived surge in both men and 
women plotted as a function of phase/trial.   
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p < .028 
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interaction effect, of phase with sequence, upon the measure of maximum 
magnitude of perceived surge [F (4, 8) = 4.245, p < 0.039, eta 0.690, power 
0.695].  Figure 4 shows menstruating women (eFP) encountering their first 
experimental session to perceive a significantly greater magnitude of surge as 
compared to women encountering their first session during their ovulatory (oP) or 
mid luteal phases (mLP).  Post hoc analyses reveal these differences to lie 
between a number of factors (see significant Tukey’s p values on Figure 4 
 
Figure 3.  Maximum magnitude rating of perceived surge in women plotted as a 
function of phase of the female menstrual cycle.   
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Figure 4.  Maximum magnitude rating of perceived surge in women plotted as a 
function of sequence of experimental sessions and phase of the female 
menstrual cycle.  
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above).  This figure elucidates how these differences appear to be focused upon 
the first sequence condition, not elicited with women encountering their second 
or third experimental sessions.    
 
p < .001 
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p < .019 
p < .009 
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4. Magnitude of Perceived Sway  
Magnitude of perceived sway data are shown in Table 14.  Once again, 
Mauchly’s test of sphericity revealed no significant effects of repeated measures 
upon these measures, neither in women alone, nor in the analysis of both groups 
considered simultaneously.  Analysis of variance of this measure failed to reveal 
a significant main effect of phase/trial or sequence, nor any significant interaction 
of these variables, in analyses of the group of women alone.  However, there 
were interesting findings revealed in the analyses of the data of both men and 
women viewed together.   
Between subjects analysis of variance of the maximum measure of 
perceived sway revealed a significant main effect of sex group [F (1, 7) = 13.457, 
 
Table 14.  Experiment 2: Illusory Motion Data: Magnitude of Perceived Sway 
 
Group                                                Magnitude of Sway 
  (0 to 10, none to maximum) 
                Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C)   
- maximum rating  4.00 (1.09) 3.14 (1.06) 2.57 (1.17) 
- final rating 2.14 (0.77) 1.00 (0.44) 2.57 (1.17) 
 
Men 
- maximum rating  0.83 (0.31) 0.50 (0.22) 2.00 (1.48) 
- final rating 0.17 (0.17) 0.17 (0.17) 0.00 (0.00) 
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 Figure 5.  Maximum magnitude rating of perceived sway plotted as a function of 
sex group of participants. 
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p < 0.008, eta 0.658, power 0.880].  Figure 5 shows the greatest levels of 
perceived sway to be reported in women as opposed to men.  Additional 
interaction effects include significant sex group by trials interaction [F (2, 14) = 
4.089, p < 0.040, eta 0.369, power 0.626], as well as sequence by trials [F (4, 14) 
= 4.198, p < 0.019, eta 0.545, power 0.803], and a significant three-way 
interaction of sex by sequence by trials [F (2, 14) = 3.995, p < 0.023, eta 0.533, 
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Figure 6.  Maximum magnitude rating of perceived sway plotted as a function of 
phase/trial by sex group.  
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power 0.781].  Figure 6 illustrates the sex group by phase/trial interaction. Post 
hoc analyses reveal a number of significant differences (Tukey’s p < .03) 
between many levels of these factors.  The data reveal a steady decrease 
among the female participants across the phase conditions, which is absent in 
repeated trials within the male participants.  Figure 7, which depicts the 
phase/trial by sequence interaction,  shows a decrease in reported sway  
p < .03 
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Figure 7.  Maximum magnitude rating of perceived sway plotted as a function of 
phase/trial by sequence of experimental sessions.  
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between the first and second sessions, among all sequence conditions 
regardless of which phase/trial participants are experiencing.  Post hoc analyses 
reveal the significant differences to lie between the OP/~OP trials of the second 
and first sequence conditions (Tukey’s p < .05), as well as eFP/~eFP of the 
second sequence condition and the OP/~OP of the first sequence condition 
(Tukey’s p < .05).  Figure 8, depicting the significant three way analysis,  
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Figure 8.  Maximum magnitude rating of perceived sway plotted as a function of 
phase/trial by sex group and sequence of experimental sessions. 
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illustrates the largest magnitudes of perceived sway to be found with women 
during eFP or OP in the second sequence condition.  Post hoc analyses reveal 
significant differences (Tukey’s p < .01) between all phases of women in the 
second sequence condition and all other data (aside from eFP in the 1st 
sequence condition and mLP in the 3rd sequence condition).  Post hoc analyses 
also find women in these two conditions data (eFP in the 1st sequence condition 
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and mLP in the 3rd sequence condition) to be significantly different from all the 
remaining data points (Tukey’s p < .01). 
 
Head Movement Data 
 
1. Linear Surge 
Linear surge head movement data are shown in Table 15.   Mauchly’s test 
of sphericity revealed no significant effects of repeated measures upon these 
measures, neither in women alone, nor in the analysis of both groups considered 
simultaneously.  Analysis of variance of this measure failed to reveal a significant 
main effect of sex group, phase/trial, or sequence, nor any significant interaction 
of these variables, in analyses of the group of women analyzed alone, nor 
between both groups of participants.   
 
Table 15.  Experiment 2: Head Movement Data: Linear Surge Head Movement 
 
Group                                              Variance of Linear Surge (cm) 
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C) 0.52 (0.29) 0.23 (0.13) .003 (0.19) 
 
Men  0.62 (0.36) -0.01 (0.46) 0.40 (0.36) 
  
 
 
 55
Table 16.  Experiment 2: Head Movement Data: Linear Sway Head Movement 
 
Group                                                 Variance of Linear Sway (cm)  
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women w/Confirmed Phases 0.42 (1.08) 1.11 (0.62) 0.35 (0.98) 
 
Men  -0.02 (0.60) 0.62 (0.82) 1.01 (0.65) 
  
 
 
 
2. Linear Sway 
Linear sway head movement data are shown in Table 16.   Mauchly’s test 
of sphericity again revealed no significant effects of repeated measures upon 
these measures, neither in women alone, nor in the analysis of both groups 
considered simultaneously.  Once again, analysis of variance of this measure 
failed to reveal a significant main effect of sex group, phase/trial, or sequence, 
nor any significant interaction of these variables, in analyses of the women alone, 
nor with both men and women.   
 
Body Movement Data 
 
1. Variance in Center of Pressure 
Variance in center of pressure data are shown in Table 17.  Once again, 
Mauchly’s test of sphericity revealed no significant effects of repeated measures  
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Table 17.  Experiment 2: Body Movement Data: Center of Pressure (COP) 
 
Group                                                        Variance of COP (cm)  
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C) 0.04 (0.009) 0.04 (0.007) 0.06 (0.01) 
 
Men  0.03 (0.004) 0.03 (0.003) 0.03 (0.004) 
  
 
 
upon these measures, neither in women alone, nor in the analysis of both groups 
considered simultaneously.  Analysis of variance of this measure failed to reveal 
a significant main effect of sex group, phase/trial, or sequence, nor any  
significant interaction of these variables, in analyses of the women alone, nor 
between both groups of participants.   
 
2. Mean Velocity of Center of Pressure 
Mean velocity in shift of center of pressure data are shown in Table 18.  
Mauchly’s test of sphericity revealed no significant effects of repeated measures 
upon these measures, neither in women alone, nor in the analysis of both groups 
considered simultaneously.  Once again, however, analysis of variance of this 
measure failed to reveal a significant main effect of sex group, phase/trial, or 
sequence, nor any significant interaction of these variables, in analyses of the 
group of women alone, nor between both groups of participants.   
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Table 18.  Experiment 2: Body Movement Data: Mean Velocity of COP 
 
Group                                                 Mean Velocity of COP (cm/sec)  
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C) 0.28 (0.04) 0.27 (0.03) 0.29 ( 0.05) 
 
Men  0.21 (0.012) 0.26 (0.06) 0.25 ( 0.06) 
  
 
 
3. Length of Sway Path 
Mean length of sway path data are shown in Table 19.  Mauchly’s test of 
sphericity revealed no significant effects of repeated measures upon these 
measures, neither in women alone, nor in the analysis of both groups considered 
simultaneously.  However, again, analysis of variance of this measure failed to 
reveal a significant main effect of sex group, phase/trial, or sequence, nor any  
 
Table 19.  Experiment 2: Body Movement Data: Length of Sway Path 
 
Group                                                     Length of Sway Path (cm) 
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C)  2.28 (0.35) 2.15 (0.27) 2.32 ( 0.36) 
 
Men  1.65 (0.08) 2.05 (0.46) 2.03 (0.45) 
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Table 20.  Experiment 2: Body Movement Data: Area of Sway Path 
 
Group                                                     Area of Sway Path (cm2) 
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C)  0.30 (0.11) 0.20 (0.07) 0.37 (0.20) 
 
Men  0.10 (0.03) 0.16 (0.05) 0.22 (0.09) 
  
 
 
 
significant interaction of these variables, in analyses of the women alone, nor in 
between male and female participants.   
 
4. Area of Sway Path 
Mean area of sway path data are shown in Table 20.  Mauchly’s test of 
sphericity revealed no significant effects of repeated measures upon these 
measures, neither in women alone, nor in the analysis of both groups considered 
simultaneously.  In addition, once again, analysis of variance of this measure 
failed to reveal a significant main effect of sex group, phase/trial, or sequence, 
nor any significant interaction of these variables, in analyses of the women alone, 
nor with both men and women.   
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Motion Sickness Data 
 
1. Tolerance 
Tolerance time data are shown in Table 21.  Mauchly’s test of sphericity 
again revealed no significant effects of repeated measures upon these 
measures, neither in women alone, nor in the analysis of both groups considered 
simultaneously.  Analysis of variance of these data failed to reveal a significant 
main effect of sex group or phase/trial, nor any significant interaction of these two 
variables.  In addition, analyses also failed to reveal any significant effect of 
sequence, neither in analyses of the group of women alone, nor in the entire 
participant group as a whole.   
 
Table 21.  Experiment 2: Motion Sickness Data: Tolerance for Stimulation 
 
Group                                                  Tolerance Time (seconds) 
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C)  1200 (0) 1200 (0) 1171 (28) 
 
Men  1200 (0) 1200 (0) 1200 (0) 
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2.  Magnitude of MS 
Magnitude of MS data are shown in Table 21.  Once again, Mauchly’s test 
of sphericity revealed no significant effects of repeated measures upon these 
measures, neither in women alone, nor in the analysis of both groups considered 
simultaneously.  Within subjects analysis of variance of this measure in men and  
women failed to reveal a significant main effect of phase or sequence, nor any 
significant interaction of these variables.  However, there were interesting 
findings revealed in the between groups analyses.   
Between subjects analysis of variance of the final reported magnitude 
rating of MS in both men and women, revealed a significant main effect of sex 
group [F (1, 7) = 5.988, p < 0.044, eta 0.461, power 0.559].   Figure 9 shows 
 
Table 22.  Experiment 2: Motion Sickness Data: Magnitude of MS 
 
Group                                                   Magnitude of MS 
  (0 to 10, none to maximum) 
                Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C)  
- maximum rating  2.57 (1.23) 1.71 (0.97) 2.57 (1.15) 
- final rating 2.57 (1.23) 1.57 (1.00) 2.57 (1.15) 
 
Men 
- maximum rating  0.67 (0.33) 0.67 (0.33) 0.83 (0.83) 
- final rating 0.17 (0.17) 0.33 (0.21) 0.50 (0.50) 
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Figure 9.  Maximum magnitude rating of MS plotted as a function of sex group of 
participants. 
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women to report far higher ratings of MS as compared to the male participants.  
Further analysis revealed an additional main effect of sequence upon both the 
maximum and final magnitude rating of MS [F (2, 7) = 5.233, p < 0.041, eta 
0.599, power 0.634; F (2, 7) = 4.897, p < 0.047, eta 0.583, power 0.604].  Figure 
10 shows the greatest final and maximum report of perceived MS to be found in 
the 3rd sequence condition.  However, post hoc analyses revealed no  
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Figure 10.  Final and maximum magnitude rating of MS in both sex groups 
plotted as function of sequence of experimental conditions.  
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statistically significant differences between these conditions, neither in the final 
nor maximum magnitude rating measures..   
In analyses of the group of women alone, while neither within or between 
subjects analysis of variance revealed any significant effects of trial/phase nor 
sequence, there was a marginal effect of sequence upon both measures in the 
between subjects analyses [F (2, 4) = 4.548, p < 0.093, eta 0.695, power 0.435, 
and F (2, 4) = 4.778, p < 0.087, eta 0.705, power 0.452].  Figure 11 shows that 
women in the third sequence of experimental sessions (mLP, then eFP, lastly 
oP) appear to report the greatest magnitudes of discomfort in the study, as 
compared to the other two sequence conditions, in both the final as well as the 
maximum reported magnitude measures..  
 
3. Difference Score 
Table 21 shows the difference score data from the symptoms of 
discomfort questionnaires completed before versus after each experimental 
session.  As Mauchly’s test of sphericity of these data reveal significant effect of 
trials, for analysis of both groups of participants [Mauchly’s W = 0.233, p < 0.013] 
as well as for the analysis of the group of women alone [Mauchly’s W = 0.036, p 
< 0.007], the Greenhouse-Geisser factor was subsequently used to correct for 
this effect.  Analysis of variance of this measure failed to reveal a significant main 
effect of sex group, phase/trial, or sequence, nor any significant interaction of 
these variables in analyses both men and women.  However, while there was 
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Figure 11.  Final and maximum magnitude rating of MS in women plotted as a 
function of sequence of experimental sessions.   
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- Not Significant - 
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Table 23.  Experiment 2: Motion Sickness Data: Difference Score of Symptom 
Checklist 
 
Group                                     Difference Score Of Symptom Checklist 
                      Mean (SD)  
 
 
  eFP/~eFP OP/~OP mLP/~mLP 
 
Women  (C) 2.71 (1.02) 3.00 (0.93) 5.43 (2.27) 
 
Men  1.17 (0.40) 1.50 (0.56) 2.67 (2.12) 
 
 
 
not a statistically significant main effect of phase/trials upon this measure in the 
group of women analyzed alone, the data appear to be approaching levels of 
significance [F (2, 8) = 4.514, p < 0.082, eta 0.530, power 0.438].  Figure 12 
reveals the increased difference scores elicited in women during the eFP as 
opposed to the two other phases of their menstrual cycle.   
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Figure 12.  Difference Score of Symptom Checklist, rating of MS in women 
plotted as a function of menstrual phase conditions.   
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CHAPTER IV: DISCUSSION 
 
Experiment 1  
Hypothesis # 1: Sex Group Æ DLL 
• Fail to reject null hypothesis.  Analyses failed to reveal a significant main 
effect of sex of the individual [sex group] upon any of the three DLL 
measures. 
Hypothesis # 2: Phase/Trial Æ DLL 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
effects of phase of the menstrual cycle [phase/trial] upon any of the three 
DLL measures, neither in all three groups or in the group of women alone.  
Hypothesis #3: Sex Group x Phase/Trial Æ DLL 
• Fail to reject null hypothesis.  Analyses failed to reveal significant 
interaction effects of sex group and phase/trial upon any of the three DLL 
measures. 
Hypothesis # 4: Sequence Æ DLL 
• Reject null hypothesis and accept alternative hypothesis.  As 
hypothesized, analyses failed to reveal a significant effect of sequence 
upon any of the three DLL measures. 
 
Little or no support was found for the hypotheses initially proposed in this 
study.  The only alternative hypothesis that was accepted was that there were no 
significant effects of sequence found upon any of the three DLL measures.  The 
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data revealed no other statistically significant effects of any of our two major 
independent variables.   
There were no significant differences revealed between men and women 
on any of the DLL measures.  In reference to symptoms of discomfort, these 
findings are in direct contradiction to a bulk of studies both in the literature as well 
as in our laboratory.  While closer examination of these data show that women 
do tend to report a greater number and severity of symptoms of discomfort, these 
differences were not statistically significant.   
In addition, there were no significant differences in any of the DLL 
measures as a function of phase of the menstrual cycle, even when examining 
the group of women alone.  While closer examination of these daily symptom 
data shows an increased report of symptoms of discomfort during menstruation 
(eFP), this difference did not reach a level of statistical significance.   
The results of this portion of the study therefore did not find support for the 
theory that sex and cyclical differences in dynamic motion environments may be 
due to a reporting bias, as similar sex differences in symptoms of discomfort 
were not reported in the absence of motion stimulation.  In that these data failed 
to reveal significant effects of the independent variables in Experiment 1, there 
was no reason to subtract the influence of these factors from data gathered in 
Experiment 2.   
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Experiment 2 
Hypothesis # 1: Sex Group Æ MS 
• Reject null hypothesis and accept alternative hypothesis.  As 
hypothesized, analyses revealed a significant main effect of sex group 
upon magnitude ratings of MS.   
Hypothesis # 2: Phase/Trial Æ MS 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
effects of phase of the menstrual cycle [phase/trial] upon any of the MS 
measures, neither in all three groups or in the group of women alone. 
Hypothesis # 3: Sex Group x Phase/Trial Æ MS 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
interaction effects of sex group with phase/trial upon any of the MS 
measures, neither in all three groups or in the group of women alone.   
Hypothesis # 4: Sequence Æ MS 
• Fail to reject null hypothesis.  Analyses revealed a significant effect of 
sequence upon the measures of magnitude ratings of MS. 
Hypothesis # 5: Sex Group Æ PI 
• Reject null hypothesis and accept alternative hypothesis.  As 
hypothesized, analyses revealed a significant interaction effect of sex 
group upon magnitude ratings of illusory motion. 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
effects of sex group upon any body movement measure. 
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• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
effects of sex group upon any head movement measure. 
Hypothesis # 6: Phase/Trial Æ PI 
• Reject null hypothesis and accept alternative hypothesis.  As 
hypothesized, analyses revealed a significant interaction effect of 
phase/trial with sequence upon magnitude ratings of illusory motion. 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
effects of phase/trial upon any body movement measure. 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
effects of phase/trial upon any head movement measure. 
Hypothesis # 7: Sex Group x Phase/Trial Æ PI 
• Reject null hypothesis and accept alternative hypothesis.  Analyses 
revealed a significant three way interaction effect of sex group and 
phase/trial with sequence upon the measures of magnitude ratings of 
illusory motion. 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
interaction effects of sex group and phase/trial upon any body movement 
measure. 
• Fail to reject null hypothesis.  Analyses failed to reveal any significant 
interaction effects of sex group and phase/trial upon any head movement 
measure. 
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Hypothesis # 8: Sequence Æ PI 
• Fail to reject null hypothesis.  Analyses revealed significant interaction 
effects of sequence with both sex group, as well as phase/trial, and a 
three way interaction of these factors upon magnitude ratings of illusory 
motion. 
• Reject null hypothesis and accept alternative hypothesis.  As 
hypothesized, analyses failed to reveal any significant effects of sequence 
upon any body movement measure. 
• Reject null hypothesis and accept alternative hypothesis.  As 
hypothesized, analyses failed to reveal any significant effects of sequence 
upon any head movement measure. 
 
While there was not support found for all hypotheses initially proposed, 
this portion of the study found greater support than the previous segment of the 
study.  Contrary to previous studies in the areas of posture and joint stability, 
there was no significant effect of the major independent variables (neither sex 
group nor phase/trial) revealed in any of our objective measures of PI.     
However, both sex group and phase/trial were significantly involved in 
magnitude ratings.  There were significant interaction effects found with these 
and the factor of sequence upon measures of magnitude ratings of perceived 
illusory motion.  The greatest reported magnitude of sway was found in the 
second session of the group of women, whose second session was confirmed by 
salivary estradiol analysis to occur during their period of ovulation.   
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In addition, measures of MS also revealed significant effects of sex group.   
Women were found to have both a greater reported magnitude of MS, as well as 
a larger difference score on symptom checklists completed before versus after 
each experimental session.   
As the sequence of experimental conditions were counterbalanced to 
control for an effect of order of experimental sessions upon the dependent 
variables, a significant effect of sequence upon these measures was not 
expected.  However, this factor was found to significantly contribute to a number 
of interaction effects, both with phase/trial and sex group, upon magnitude 
ratings of illusory motion.  The third sequence (mLP-eFP-OP) appearing to elicit 
higher magnitude ratings of MS as compared to the other two experimental 
sequences.   
 
Conclusions 
The results of Experiment 1 were surprising in that they did not replicate 
the fluctuations in symptomatology, which have been found to normally occur 
over the course of the menstrual cycle within many non-clinical samples of 
women (Brooks-Gunn & Ruble, 1992; Woods, 1999).  A substantial body of 
literature supports the existence of such menstrual cycle fluctuations (Palmer, 
Lambert & Richards, 1991; Sveinsdotter & Backstrom, 2000), yet this study found 
no significant effects of phase upon measures of symptoms of discomfort.  
Although analyses of variance failed to find a significant influence of this factor 
upon any the Daily Symptom measure, both the effect sizes and observed power  
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Table 24.  Experiment 1: Summary Table of Results of Analysis of Variance of 
Daily Symptom Data 
 
Source   df F Sig. Partial        Observed  
                    Eta Squared   Power 
 
 
Phase/Trial within Sex Groups  2 2.869 0.065 0.096 0.539 
 
 
 
Phase/Trial by Sex Group 
   2 0.021 0.979 0.001 0.053 
 
Error   54 
 
 
Phase/Trial within Women (C) 
   2 2.904 0.067 0.133 0.534 
 
Error   38 
 
 
 
values for these data were rather low (see Table 24).  This suggests that it might 
be possible to attain a level of significance with a much larger sample of women, 
particularly if it is possible to confirm the phases of their menstrual cycles.  
In addition, although we did not find a significant interaction between the 
independent variables (sex group and phase/trial) in Experiment 2 (which would 
indicate an integration of these components within the mechanisms of MS and 
PI), the other significant effects of these factors, when viewed in combination with 
the data from Experiment 1, suggest that the sex differences in MS measures 
elicited may still be a feature of more than a reporting bias.  As the second 
experiment revealed a significant sex difference in levels of reported discomfort, 
which was not found during the baseline portion of the study (the first 
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experiment) there appear to be differences between men and women, that are 
elicited upon exposure to motion stimulation, which may not be merely a factor of 
differing reporting styles.   
Questions also continue to persist as to why this study failed to replicate 
previous research investigating the influence of the menstrual cycle upon 
measures of PI.   As mentioned previously, research in sports medicine has 
revealed significant sex and phase differences in the rates of sports related 
injuries, implicated female reproductive hormones in PI (Hewett, 2000).  As levels 
of estrogen have been found to be negatively related to different aspects of 
biomechanical stability (Booth & Tipton, 1970; Sarwar, Beltran & Rutherford, 
1996), increased PI was expected to occur during periods of confirmed ovulation.  
However, the current findings may be attributable to the specific methods of 
measuring PI in the present study, which utilized center of pressure and head 
movement measures, which were not used in above-mentioned studies.   
In addition, while the second experiment failed to find any significant 
influence of phase of the menstrual cycle upon MS, it does not preclude this as a 
contributing factor.  The main effect of sex group upon MS measures, which 
replicated a number of studies previously conducted in our laboratories 
(Flanagan, May & Dobie, 2002, 2004a, 2004b, 2005), indicates that there may be 
other sex-related factors, which have yet to be fully addressed.   
There were a number of weaknesses in the present study that may have 
influenced the outcome elicited.  For instance, although 18 women participated in 
this portion of the study, saliva analysis found the success rate of our sampling 
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technique to be 38.9%; only seven of the women sampled confirmed to have 
been tested at the appropriate time to sample the target phases of their 
menstrual cycles, with low levels of salivary estradiol during the mid-luteal phase, 
and higher levels during the ovulatory phase.  A more precise sampling method 
might enable a higher rate of successful exposure, thereby enabling a larger 
sample to contribute to the data set entering the final stages of analyses.  
Although analyses of variance failed to find a significant influence of this factor 
upon any of the MS measures, both the effect sizes and observed power values 
for these data were rather low (see Table 25).  This suggests that it might be 
possible to attain a level of significance with a much larger sample of women 
tested during their confirmed phases of their menstrual cycles.  This may explain 
why we failed to replicate the findings of Grunfeld and colleagues (Grunfeld, et  
al., 1998; Grunfeld & Gresty, 1998), who found decreased MS during ovulation of 
34 female participants in a 9 month yacht race. 
As mentioned previously, however, there have been a number of studies 
conducted by Cheung and colleagues (Cheung & Hofer, 2002; Cheung, Heskin, 
Hofer & Gagnon, 2001), which have also failed to find significant differences in 
the incidence of symptomatology in women as a function of the phase of their 
menstrual cycle.  They suggested that differences in MS elicited between men 
and women might be related to participants’ level of anxiety upon stimulation 
(Cheung, Heskin, Hofer & Gagnon, 2001).  Therefore, it might be appropriate to 
measure levels of anxiety and levels of salivary cortisol in future studies, which 
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Table 25.  Experiment 2: Summary Table of Results of Analysis of Variance of 
Motion Sickness Data 
 
Source Measure  df F Sig. Partial        Observed  
                    Eta Squared   Power 
 
 
Phase/Trial within both Sex Groups 
 
 Tolerance  2 0.412 0.670 0.056 0.104 
 
 Maximum MS 2 0.383 0.689 0.052 0.100 
 
 Final MS  2 0.580 0.573 0.076 0.127 
 
 Difference  2 1.600 0.156 0.233 0.363 
 Score 
 
 
Phase/Trial by Sex Group 
 
 Tolerance  2 0.412 0.670 0056 0.104 
 
 Maximum MS 4 0.256 0.778 0.035 0.083 
 
 Final MS  4 0.620 0.552 0.081 0.133 
 
 Difference  2 0.126 0.883 0.018 0.062 
 Score 
 
Error   14 
 
 
Phase/Trial within Women (C) 
 
 Tolerance  2 0.500 0.624 0.111 0.106 
 
 Maximum MS 2 0.456 0.649 0.102 0.101 
 
 Final MS  2 0.713 0.519 0.151 0.132 
 
 Difference  2 4.514 0.082 0.540 0.438 
 Score 
 
Error   8 
 
 
 
clarify another possible factor contributing to the sex differences found with 
motion stimulation.  
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 In conclusion, this study has yielded a challenge.  Through its allusion to 
statistical significance, power and effect size, form appears to be lying just below 
the surface of these data.  The influence of these factors upon responses to 
virtual motion stimulation can be further clarified with continued investigation.  
Future studies may address more precise periods of the female menstrual cycle, 
as well increased sample size of female participants.  In addition, incorporating 
measures of anxiety, as well as different methods of measuring PI and MS may 
further elucidate any sex or phase differences in these types of responses to 
virtual motion environments.     
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_______________________________________________________________________________ 
 
Please check the appropriate response (A or B). 
 
  A. I would like to complete this questionnaire and I understand that I may be contacted in the 
future to participate in research experiments. 
 
 
Name (please print):  _______________________________________________________ 
 
Email address: _______________________________  Telephone #: _________________ 
  B. While I would like to complete the questionnaire, I do not wish to be contacted in the future 
to participate in research experiments.  
_______________________________________________________________________________ 
 
Please answer each of the questions below to indicate whether you have ever had any of 
the following medical conditions, noting when the condition started and whether it persists 
currently.   
 
Condition   No Yes Date of Onset Current (Y/N) 
 
Visual Condition,  
If yes, please specify:  
    
 
Vestibular (balance) Condition,  
If yes, please specify:  
    
 
Heart Condition,  
If yes, please specify:  
    
 
Neurological Condition,  
If yes, please specify:  
    
 
Psychiatric Condition,  
If yes, please specify:  
    
 
Head Injury     
 
Epilepsy (seizures)     
 
Chronic Pain,  
If yes, specify type:  
    
 
Any Current Medication? 
birth control  
hormone supplements 
insulin 
other,  
If yes, please specify:  
     
 
Females:  
- Pregnancy  
- Menstrual Irregularity or Pain  
If yes, please specify: 
1st day of your last menstrual per
please specify: 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
Age:  ________     Gender  (check one) :    Male       Female 
Predominant Ethnic Origin (check one):   White, non-Hispanic   African-American, Black   Hispanic  
  Native American   Asian or Pacific Islander (including Indian sub-continent)   Choose not to respond  
 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
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1. Title of Research Study:  Daily Living Study 
 
2. Project Directors:    Moira B. Flanagan, M.S. 
   James G. May, Ph.D.  
   Psychology Dept., 2001Geology-Psychology Building, UNO 280-6770 
 
3 Purpose  
The purpose of this experiment is to examine changes in daily activities and feelings of well-
being throughout a monthly cycle. 
 
4. Procedures 
In this study you will be asked to complete a series of questionnaires related to your activities of 
daily living.  You will initially be asked to complete a brief questionnaire regarding your general 
state of health.  You will be given instructions as to how to complete a series of Daily Living 
Logs (D.L.L.’s).  The first part will consist of a daily activities checklist, the second part, a 
consumption checklist; the third part, a daily symptom checklist.  You will be asked to complete 
these questionnaires once a day for 40 days.  Completed forms must be submitted every day, 
and can be turned in electronically (via email) or in person (to the psychology department).  It is 
very important that the questionnaires be completed on a daily basis.  However, your 
participation in this study will be halted at any time, if you so request.     
 
5. Potential Risks or Discomforts 
Some people may become uncomfortable completing these questionnaires on a daily basis.   
However, if at any point you become so uncomfortable that you cannot continue, your 
participation in the study can be terminated.  If you wish to discuss these or any other 
discomforts you may experience, you may call the Project Director at the phone number listed 
above. 
 
6. Potential Benefits to You or Others 
As a participant, you may gain valuable knowledge and/or awareness of your own daily living 
fluctuations, as well as learn more about research in the field of psychology.  
7. Alternative Procedures 
Your participation is entirely voluntary and you may withdraw consent and terminate 
participation at any time without consequence.  In addition, your instructor has indicated 
alternative means for your involvement with research within the psychology department. 
 
8. Protection of Confidentiality 
 Your confidentiality will be ensured through the assignment of a code to your data.   
 
I have been fully informed of the above-described procedure with its possible benefits and 
risks and I have given permission for participation in this study.  
 
                                                                                                                                        . 
Signature of Subject    Name of Subject (Print)  Date 
 
 
                                                                                                                                        . 
Signature of Person Obtaining Consent Name of Person Obtaining Consent Date 
 
CONSENT FORM
Appendix B
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_____________________________________________________________________________ 
 
Please return completed questionnaires to the Psychology Department in the Geology-
Psychology Building, room 2001 attention Moira Flanagan  
or email to mflanaga@uno.edu  
 
DAILY LIVING LOGS 
 
Dr. Jim May’s Laboratory in Department of Psychology at the University of New Orleans would 
like to invite you to become involved in furthering our understanding of the relationship between 
different aspects of daily living.  Your participation in these studies may further your own 
understanding of these processes, as well as possibly earn you extra credit in your psychology 
course.   
 
The data collected in these questionnaires will be used for research purposes only, and full 
confidentiality will be maintained.  Individual responses will never be released to anyone not 
involved in the conduct of these projects.   
 
The code given to your data will be _________________________________________________ 
 
Please make note of this code on each log you complete.  Your assistance in keeping your 
records confidential is appreciated. 
 
These logs are designed to survey prospective participants’ personal experiences.  The aim of 
this study is to gather information that may be useful in generating answers to questions 
regarding the relationship between different aspects of daily living.  The logs are divided into 
three parts, an "Activity Checklist", a “Consumption Checklist”, and a "Symptom Checklist".   
 
The first part (Activity Checklist) relates to the types of activities you may have 
engaged in within the past 24 hours.   
 
The second part (Consumption Checklist) asks about different foods, beverages, 
and medications that you might have consumed within the past 24 hours. 
 
The third part (Symptom Checklist) records any feelings of discomfort you may 
have experienced within the past 24 hours. 
 
These logs must be returned to the experimenter every 24-hours for forty days. 
 
Responses may be : 
 
- emailed to mflanaga@uno.edu, 
 
- completed online at http://www.geocities.com/mbflanagan2002/dll.html,  
 
- or submitted at the psychology department office (GP 2001), to the  
attention of Moira Flanagan. 
 
_____________________________________________________________________________ 
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Personal Code: _______________________________________________________________ 
 
Date:  _______________________________________________________________________ 
 
 
D. L. L. ACTIVITY CHECKLIST 
 
 
Please respond to the list of activities by indicating the amount of time that you spent engaged in 
the specific activity within the last 24 hours.    
 
If you did NOT engage in that activity, leave the response area blank. 
 
If you DID engaged in that activity, indicate the amount of time you spent on the activity, rounding 
UP to the nearest whole hour. 
 
 
 
ACTIVITIES TIME ACTIVITIES TIME 
Exercise activities  # hours Transportation activities # hours 
Baseball / Softball  Airplane riding  
Basketball  Automobile riding  
Bicycle riding  Bicycle riding   
Calisthenics  Bus riding     
Cheerleading  Driving (automobile, bus, truck, …)  
Dancing  Elevator riding    
Football  Escalator riding  
Gymnastics  Large boat riding (ships, …)  
Hockey  Small boat riding  (canoe, rafts, …)  
Martial arts  Streetcar riding  
Running / Jogging  Train riding  
Skating / Blading  Walking    
Skiing    
Soccer  Miscellaneous activities # hours 
Swimming  Amusement park rides  
Tennis  Computer or video games  
Volleyball  In Class / Studying / Reading  
Walking  Merry-go-rounds  
Weight lifting  Shopping (grocery, clothes, etc…)  
Wrestling  Sleeping / Napping / Resting  
Yoga / Pilates  Swing / Hammocks  
  
 
Socializing  
Television home-viewing  
Movies (movie theaters and IMAX)   
Other, please specify:  
 
 
Work, please specify title:  
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Personal Code: _______________________________________________________________ 
 
Date:  ________________________________________________________________________ 
 
 
D. L. L. CONSUMPTION CHECKLIST 
 
Please respond to the list of substances listed below, indicating if you have consumed any of 
these within the past 24 hours.    
 
If you did NOT consume any of a substance, leave the response area blank. 
 
If you DID consume the substance, please indicate the approximate quantity that you ingested 
(for example, 3 beverages, 2 cigarettes, ...). 
 
 
 
 
 SUBSTANCES QUANTITY 
 
Alcoholic Beverages 
     i.e. beer, wine, mixed drinks 
 
 
 
Caffeinated Beverages  
     i.e., coffee, tea, soft drinks 
 
 
 
Tobacco Products  
     i.e., cigarettes, cigars, pipes   
 
 
 
 
 
Drugs or Medications 
     prescription, please specify: 
 
     non-prescription, please specify: 
 
     other, please specify: 
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Personal Code: _______________________________________________________________ 
 
Date:  ________________________________________________________________________ 
 
D. L. L. SYMPTOM CHECKLIST 
 
Please respond to the list of symptoms below, indicating any feelings of discomfort you may have 
experienced within the past 24 hours.   
 
If you did NOT have the symptom, leave the response area blank.   
 
If you DID experience the symptom, please rate the extent of the symptom.  The response ratings 
are:  
1 = Slight 2 = Moderate 3 = Severe 
 
SYMPTOMS RATING SYMPTOMS RATING SYMPTOMS RATING 
Achiness  Drowsiness  Muscle Cramps  
Anxiety  Earache  Muscle Soreness  
Belching  Faintness  Nausea   
Bloating/ 
Swelling  Fatigue  Nervous  
Body warmth  Feverish  
Boredom  Fullness of head  
 
 
Pain, specify  
 
Breast 
tenderness  
General 
discomfort  Queasy  
Breathing 
difficulties  Headache  Restless  
Chills  Heartburn  Sighing/  yawning  
Cold sweating  Hearing problems  Sneezing  
Confusion  Increased salivation  Sore throat  
Congestion  Indigestion  Stomach awareness   
Constipation  Insomnia  Stuffy head  
Cough  Irritability  Vision problem  
Dental 
irritation  
LOSS of 
appetite  Vomiting  
Depression  Menstrual Bleeding  Weakness  
Diarrhea  Menstrual Cramps  
Dizziness  Migraine  
 
 
Other, specify  
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1. Title of Research Study:  Motion Perception Experiment 
 
 
2. Project Directors:   Moira B. Flanagan, M.S. 
       James G. May, Ph.D.  
       Psychology Dept., 2001Geology-Psychology Building, UNO 280-6770 
 
3. Purpose 
The purpose of this experiment is to examine changes motion perception at three different 
times in a single month.   
 
5. Procedures 
In this study you will be asked to come into our laboratory for 40 minute sessions, on three 
separate occasions over the next month.  You will wear a safety helmet and stand barefoot 
on a small platform while watching a rotating spiral for no more than 20 minutes.  We will 
measure your head and body movement, and you will be asked to complete brief 
questionnaires before and after each session.  However, if at any point you become 
uncomfortable and feel that you cannot continue, your participation in the study can be 
terminated. 
 
 
5. Potential Risks or Discomforts 
Some people may become uncomfortable watching this type of visually depicted motion.   If 
at any point you become so uncomfortable that you feel that you cannot continue, your 
participation in the study can be terminated.  If you wish to discuss these or any other 
discomforts you may experience, you may call the Project Director at the phone number 
listed above. 
 
 
6. Potential Benefits to You or Others 
As a participant, you may gain valuable knowledge and/or awareness of your own 
fluctuations in motion perception, as well as learn more about research in the field of 
psychology.  
9. Alternative Procedures 
Your participation is entirely voluntary and you may withdraw consent and terminate 
participation at any time without consequence.  In addition, your instructor has indicated 
alternative means for your involvement with research within the psychology department. 
 
 
 
10. Protection of Confidentiality 
 Your confidentiality will be ensured through the assignment of a code to your data.   
 
 
 
 
I have been fully informed of the above-described procedure with its possible benefits and 
risks and I have given permission for participation in this study.  
 
 
 
                                                                                                                                     . 
Signature of Subject   Name of Subject (Print)  Date 
 
 
                                                                                                                                     . 
Signature of Person Obtaining Consent Name of Person Obtaining Consent Date 
CONSENT FORM
Appendix D
103 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix E: 
Human Subject Review Committee Forms 
 
104 
 
Appendix E
105  
Appendix E
106 
Appendix E
107 
Appendix E
108 
VITA 
 
Moira Flanagan was born in Alexandria, Virginia, where she began her 
travels internationally with her family, as a daughter of a U.S. Diplomatic service 
officer.  Moira received a Bachelor of Science degree in Sociology from Virginia 
Tech in 1993, with a minor in Psychology.  She earned a Master of Science 
degree from the University of New Orleans in Applied Biopsychology in 2001.  As 
a doctoral student, Moira’s academic and professional achievements have been 
recognized both locally and internationally.  She received the UNO Crescent City 
Doctoral Scholarship (2003-2005), the Young Investigator Award from the Space 
Medicine Branch of the Aerospace Medical Association (2003), UNO 
Distinguished Graduate Student, Certificate of Commendation (2003), the UNO 
LEQSF Fellowship (1999-2003), and two Travel Awards from the Neuroscience 
Center of Excellence of the Louisiana State University Health Science Center 
School of Medicine (2001-2002).  She has also published a number of research 
articles in peer-reviewed journals, and has presented the results of her research 
a numerous local, national, and international conferences.  She has attained a 
wealth of experience through her employment with the National Biodynamics 
Laboratory, and is also currently working with the Tulane University Medical 
School in the Department of Psychiatry and Neurology as a Medical Research 
Associate.  Her current research interests focus upon various aspects of motion 
perception, including biomechanics and kinesiology (such as how the head and 
body move in response to perceived motion), eye movement responses to 
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motion, and the influence of sex and hormones to these measures.  Moira 
aspires to continue her research endeavors in these areas, as she begins her 
pursuit of a post doctoral research position.   
 
 
 
 
